Rienso: hypersensitivity warnings strengthened

Takeda has issued a letter to healthcare professionals about the risk of serious hypersensitivity reactions associated with the use of its injectable colloidal iron-carbohydrate complex, ferumoxytol (Rienso).

Rienso (ferumoxytol) is indicated for the treatment of iron-deficiency anaemia in chronic kidney disease. | SCIENCE PHOTO LIBRARY
Rienso (ferumoxytol) is indicated for the treatment of iron-deficiency anaemia in chronic kidney disease. | SCIENCE PHOTO LIBRARY

In agreement with the European Medicines Agency (EMA) and the Medicines and Healthcare Products Regulatory Agency (MHRA), the following changes have been made to the prescribing information for Rienso to mitigate the risk of serious hypersensitivity reactions:

  • Rienso is now contraindicated in patients with any history of drug allergy, including previous hypersensitivity to other parenteral iron products
  • Rienso should only be administered as an intravenous infusion after dilution in 50–250ml of sterile 0.9% NaCl or sterile 5% glucose and must be given over at least 15 minutes
  • Patients should be monitored for signs and symptoms of hypersensitivity reactions, including blood pressure and pulse rate, during and for at least 30 minutes after completion of the infusion
  • Patients should be advised to seek urgent medical attention if they start to feel unwell
  • Rienso must only be administered by trained staff in an environment where resuscitation facilities are available

View Rienso drug record

Further information: Takeda

Follow MIMS on Twitter

Sign up for MIMS bulletins

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases